

# Ceregin

(Co-dergocrine mesilate)

سیریجن  
(کو-ڈرگورائن میسیلیٹ)

گولیاں اور اورل سلوشن

## Tablet & Oral Solution

### COMPOSITION:

#### Each tablet contains:

Co-dergocrine mesilate (U.S.P.).....4.5 mg & 1.5 mg  
Product Complies U.S.P. Specs.

#### Each 1ml contains:

Co-dergocrine mesilate (U.S.P.).....1 mg  
Product Complies U.S.P. Specs.

### PROPERTIES:

Animal studies indicate that Co-dergocrine mesilate (**Ceregin**) modifies cerebral metabolism, cerebral neurotransmission and evidence is available for a stimulant effect on dopamine and serotonin receptors and for a blocking effect at alpha-adrenoceptor sites. Co-dergocrine mesilate (**Ceregin**) improves impaired cerebral metabolic function, which is supported by histochemical investigations of enzyme activity of the brain, notably in the power spectra of the electroencephalogram (EEG). This beneficial effect on the EEG has been confirmed by experimental studies in man.

Co-dergocrine mesilate (**Ceregin**) has also been found to shorten cerebral circulation time, due to the action at the microcirculatory level and this effect is brought about as a result of the improvement in neuronal metabolism.

Controlled clinical trials have shown that Co-dergocrine mesilate (**Ceregin**) is effective in improving many of the symptoms of cerebral insufficiency in the areas of self-care, social behavior, emotional state and mental performance.

Co-dergocrine mesilate (**Ceregin**) also has stabilizing effect on the tone of cranial vessels, and this accounts for its prophylactic effect in migraine and dizziness.

### PHARMACOKINETICS :

The absorption of Co-dergocrine mesilate (**Ceregin**) after oral administration amounts to 25%. Maximum plasma concentrations are reached after 0.5 to 1.5 hours. Due to the first-pass effect, the bioavailability is between 5 and 12%. The volume of distribution is 1100 liters (approx. 16L /kg) and the plasma protein binding 81%. The elimination is biphasic with a short half-life of 1.5 to 2.5 hours ( $\alpha$  - Phase) and a longer one of 13 to 15 hours ( $\beta$ -Phase). Co-dergocrine mesilate (**Ceregin**) is mainly excreted with the bile into the faeces. Elimination in the urine amounts to 2% for the unchanged drug and its metabolites and to less than 1% for the unchanged substance alone. Total clearance is about 1800 ml/mm. In elderly patients the plasma concentrations are some what higher than in younger subjects. In patients with renal insufficiency, a reduction in dose is scarcely necessary because only a minor amount of the drug and its metabolites is eliminated by the kidney.

### INDICATIONS :

\* Symptoms and signs of cerebral insufficiency (mental deterioration) like dizziness, headaches, poor concentration, disorientation, impaired memory; lack of initiative, mood-depression, unsociability, difficulties with daily

living activities and with self-care.

- \* Acute cerebrovascular disease.
- \* Migraine and vascular headaches (preventive treatment only)
- \* Dizziness and Vertigo of different origin.

### DOSAGE:

1.5mg 2 to 3 times daily preferably before meals or 4.5mg once daily before breakfast for 3 months or more. Course of treatment may be repeated if requires.

### CONTRAINDICATION:

Known hypersensitivity to the drug.

### SIDE EFFECTS:

Nasal stuffiness, transient nausea and gastric upsets may occur occasionally, but are usually prevented by taking the drug with food. In the majority of cases, side effects disappear without specific measures being taken.

### TREATMENT OF OVERDOSAGE:

No cases with severe signs or symptoms of overdosage are known.

### INSTRUCTIONS:

Store below 30°C in a dry place, protect from light.

To be dispensed on the prescription of a registered medical practitioner only. Keep out of the reach of children.

**NOTE:** when co-dergocrine mesilate is prescribed or demanded, Co-dergocrine mesilate (B.P.) shall be dispensed or supplied.

### PRESENTATION :

**Ceregin Tablets 1.5 mg:** Available in blister pack of 3 x 10's.

**Ceregin Tablets 4.5 mg:** Available in blister pack of 1 x 10's.

**Ceregin Oral Solution 1 mg / ml:** 30 ml in bottle.

## ہدایات:

دوا کو ۳۰ ڈگری سینٹی گریڈ سے کم درجہ حرارت پر روشنی سے بچا کر خشک جگہ پر رکھیں۔  
صرف مستند معالج کے نسخے پر فروخت کریں۔  
ڈاکٹر کی ہدایت کے مطابق استعمال کریں۔  
بچوں کی پہنچ سے دور رکھیں۔

Manufactured by:

**Platinum**

Pharmaceuticals (Pvt.) Ltd.  
A 20 North Western Industrial Zone,  
Bin Qasim, Karachi-75020, Pakistan.

QAR No. AW20-0619